# Tavros Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/tavros-therapeutics

- Industry: Biotechnology
- Headquarters: Durham, US
- Website: www.tavrostx.com
- Total disclosed funding: $8.5M
- Latest round: Seed (Sep 27, 2022)
- Investors on record: 4

## About

Based in North Carolina, US, and founded in 2019 by its CEO Eoin McDonnell, and co-founders Kris Wood, and Greg Mossinghoff, Tavros Therapeutics, Inc. operates as a biotechnology research company that focuses on discovering and developing cancer treatments. In September 2022, Tavros Therapeutics, Inc. raised USD 7.5 million in seed funding co-led by KdT Ventures and returning investor Piedmont Capital Partners, with participation from Alexandria Venture Investments.

Tavros Therapeutics, Inc. discovers and develops cancer therapies by using a combination of functional and computational genomic approaches to uncover vulnerabilities within the tumor to discover context-specific cancer drugs and targets. The company also leverages its proprietary platform and map of useful synthetic lethal relationships to build a pipeline of category-defining small-molecule drug candidates.

The company plans to use the seed funding to further develop its product research and hire staff as it plans for market expansion.

## Funding rounds

- Seed, Sep 27, 2022, $7.5M — Alexandria Venture Investments, KdT Ventures, Piedmont Capital Partners
- Seed, Mar 2, 2020, $1M — Piedmont Capital Investments

## Investors

- Piedmont Capital Investments (https://capitalatlas.ai/funds/piedmont-capital-investments) — Seed
- Alexandria Venture Investments (https://capitalatlas.ai/funds/alexandria-venture-investments) — Seed
- KdT Ventures (https://capitalatlas.ai/funds/kdt-ventures) — Seed
- Piedmont Capital Partners — Seed